Opioid Epidemic: State of Emergency

Learn about Innovations to Fight the Opioid Crisis on November 29, 2017 at The Universities at Shady Grove.

Hear from expert Dr. Nora Volkow, Director, National Institute on Drug Abuse, National Institutes of Health, on a rare local appearance. 

Opioid misuse and addiction is an ongoing and rapidly evolving public health crisis. Millions of Americans suffer from opioid use disorder, and millions more suffer from chronic pain. The urgency and scale of this crisis calls for innovative, scientific solutions. As part of a government-wide effort to address this crisis, NIH is supplementing existing research efforts with a public-private collaborative research initiative to address new and innovative medications to treat opioid addiction; strategies to prevent and reverse opioid overdose; and safe, effective, and non-addictive ways to manage chronic pain.

Dr. Volkow will speak about our current understanding of the opioid crisis nationally and locally, what research has taught us about addiction, its prevention and treatment, and how science can help end the opioid crisis once and for all.

American Gene Technologies
9640 Medical Center Dr.
Rockville, MD 20850
info@americangene.com

AGT BUILDS MONTGOMERY COUNTY GENE & CELL THERAPY MOMENTUM

September 25, 2017. Montgomery County, MD:  American Gene Technologies (AGT), a private Maryland biotechnology company developing cures and treatments for Infectious diseases, cancers and monogenic disorders, will celebrate the grand opening of its new 24,000 sq. ft. laboratory and offices. From its new location, AGT will begin clinical trials for its HIV Functional Cure therapeutic in the next six months.

The ribbon cutting ceremony highlights AGT’s commitment to biotechnology in Maryland and will take place at its new location 9640 Medical Center Dr., Rockville, MD 20850 between 1-4pm on October 23^rd.

The new AGT expansion will allow for acceleration of gene and cell therapeutic development laboratories supporting the HIV Functional Cure project that is expected to enter the clinic early next year, as well as to sustain the momentum of phenylketonuria and immuno-oncology therapeutics anticipated for clinical activities in late 2019. These early-stage programs represent substantial assets backed by an impressive IP portfolio. The new offices will support the company’s expected growth through early 2020.

Specialized laboratories within the building will cover an impressive 11,500 sq. ft. of space. These include both a Vector Production Facility that allows the company to reliably produce research-grade lentivirus vector batches for cell and animal experiments, and a Translational Science Laboratory to enable broad validation of gene therapy drug candidates to further build AGT’s extensive vector asset library.

The company’s commitment to the local economy and job market is reflected in its plans to fill several positions over the coming months and into the first quarter of 2018. These include roles in clinical affairs, research and development, laboratory technicians, and others. In addition to providing space for new employees, AGT’s new location has office clusters to inspire greater collaboration and interaction among groups, as well as extensive meeting space for vendor and/or collaborator interactions.

“We are delighted to be expanding our space here in Maryland, and are grateful to Maryland Tech Council for their support” said AGT’s CEO Jeff Galvin. “Our new space will not only help to make product research, development, and testing more efficient and effective, but also enable us to further contribute to the growth of Maryland’s biotechnology sector. This expansion continues our commitment to provide job opportunities and growth within our local community.”

__________

For information on how to attend the event, please contact: Connie Ezerski, cezerski@americangene.com.

For media inquiries, please contact:  Sasha Whitaker, swhitaker@americangene.com.

About AGT

AGT is developing and commercializing genetic medicines targeting major diseases, including HIV/AIDS, phenylketonuria (PKU), and hepatocellular carcinoma (liver cancer). Its drug candidates have achieved initial proof-of-concept in preclinical studies and have the potential to deliver cost-effective therapies that provide superior targeting and improved potency with fewer side effects. AGT’s drugs will treat symptomatic disease but are intended to provide durable cures that extend the length and improve the quality of patients’ lives.

https://www.americangene.com/

MTC Updates

We’ve Moved and Announced our Signature Events!

Please update your records.

TC’s new headquarters will be located at Launch Workplaces in Gaithersburg MD, 9841 Washingtonian Boulevard, Suite 200, Gaithersburg MD 20878. Visit us online for the most up-to-date details on our programs and events.